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Abstract
The U.S. opioid epidemic is a critical public health problem. As substance use and misuse 
typically begin in adolescence and emerging adulthood, there is a critical need for prevention 
efforts for this key developmental period to disrupt opioid misuse trajectories, reducing morbidity 
and mortality [e.g., overdose, development of opioid use disorders (OUD)]. This article describes 
the current state of research focusing on prescription opioid misuse (POM) among adolescents and 
emerging adults (A/EAs) in the U.S. Given the rapidly changing nature of the opioid epidemic, we 
applied PRISMA Scoping Review (PRISMA-ScR) guidelines to identify empirical articles 
published in the past 5 years (January 2013 - September 2018) from nine databases examining 
POM among A/EAs (ages 10-25) in the U.S. Seventy-six articles met our inclusion criteria 
focusing on POM in the following areas: cross-sectional surveys (n=60), longitudinal cohort 
studies (n=5), objective, non-self-reported data sources (n=9), and interventions (n=2). Final 
charted data elements were organized by methodology and sample, with results tables describing 
design, sample, interventions (where applicable), outcomes, and limitations. Most studies focused 
on the epidemiology of POM and risk/protective factors, including demographics (e.g., sex, race), 
individual (e.g., substance use, mental health), and social (e.g., peer substance use). Despite annual 
national surveys conducted, longitudinal studies examining markers of initiation and escalation of 
prescription opioid misuse (e.g., repeated overdoses, time to misuse) are lacking. Importantly, few 
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evidence-based prevention or early intervention programs were identified. Future research should 
examine longitudinal trajectories of POM, as well as adaptation and implementation of promising 
prevention approaches.
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Introduction
The United States’ (U.S.) opioid epidemic is a serious public health problem [1] given 
opioid-related overdose deaths [1–5], underscoring the need for programs to prevent the 
initiation and escalation among adolescents and emerging adults (A/EAs). Prescription 
opioid misuse (POM, in this review: medical misuse of prescription opioids [POs] for 
reasons other than prescribed [i.e., to get high], or not taken as prescribed [e.g., higher doses, 
crushing and snorting, injecting], and/or use without a prescription) has spurred the current 
epidemic [3], with significant morbidity and mortality. POM is implicated in 46 deaths per 
day in the U.S.; accounting for more than one-third of opioid-related overdose deaths [1]. 
PO consumption via non-injection routes is often a precursor to using more potent, high-risk 
street opioids (i.e., heroin, fentanyl analogs; [6, 7]) with more hazardous routes of 
administration (e.g., injection). Current epidemiological figures support a developmental 
pattern to POM, like other misused substances (e.g., alcohol, cannabis), with initiation 
typically in adolescence, and prevalence peaking during emerging adulthood (and declining 
thereafter).
It is critical to synthesize recent knowledge to inform priorities for prevention research, 
particularly for adolescents and emerging adults (A/EAs), to prevent initiation of POM and 
escalation to consequences such as impaired functioning and/or OUD given earlier initiation 
of POM (in particular non-medical use) is associated with increased odds of later OUD [8]. 
Recent POM literature reviews among A/EAs are generally lacking; prior reviews focused 
on non-medical prescription drug use, not POs specifically [9, 10]. In one exception, a 
systematic review and meta-analysis of articles from 1990 to 2014 reported POM 
prevalence, finding past-year prevalence in 11-30-year-olds ranged from <1% to 16.3%, 
increasing approximately 0.40% per year across 1993 to 2010 [11]. A prior descriptive 
review summarized POM risk factors relevant for pediatric oncology treatment (before 
2015), which included: female sex, older age, academic problems, childhood sexual trauma, 
prior opioid prescriptions, other substance use, psychiatric concerns, and peer influences 
[12].
Extending prior work, we conducted a scoping review of recent U.S. literature (that included 
data from 2010 or later), characterizing the current state of knowledge of POM among 
A/EAs in order to inform research and interventions focusing on prevention of POM 
initiation and escalation. A scoping review was chosen because, consistent with prior 
definitions [13], we sought to provide an overview of current research in a relatively broad 
field with a variety of study designs. We address research questions pertaining to POM 
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prevalence, risk and protective factors, trajectories of use and misuse, and interventions 
among A/EAs in the U.S. We focus on POs, as opposed to heroin or fentanyl as POM 
typically occurs before heroin/fentanyl initiation [6, 7] and because rates of heroin/fentanyl 
use among A/EAs are quite low [14]. Further, the purpose of this review is to inform POM 
prevention efforts among A/EAs in the context of the current U.S. opioid epidemic. We 
examine POM broadly, given varied definitions of medical and non-medical misuse [11]. We 
describe results for adolescent-only, EA-only, and combined A/EA samples separately, given 
developmental changes and the potential need to tailor interventions and research studies for 
different ages. Note that topics including interventions delivered in specialty treatment for 
OUD (e.g., medication assisted treatment) and examining the impact of legal (e.g., 
prescription drug monitoring programs [PDMPs]) or institutional policies (e.g., 
implementation of prescribing guidelines, physician education) were outside the scope of 
this review which sought to illuminate gaps and directions for future prevention research and 
programming delivered to A/EAs directly.
Methods
Informed by Arksey and O’Malley’s [13] framework for scoping reviews and the PRISMA 
extension for Scoping Reviews (PRISMA-ScR) reporting guidelines [15], we: 1) identified 
research questions, 2) searched for relevant studies, 3) selected studies meeting inclusion 
criteria, 4) abstracted data from selected studies, and 5) organized and report results. Per 
PRISMA-ScR guidelines, we describe the protocol for this review below. Note that scoping 
reviews do not provide a quality assessment or critical appraisal nor is pooling of data 
conducted [13, 15]. This research was exempt from institutional review board approval.
Literature Search.
We systematically searched nine databases from two providers, EBSCO and Embase, with 
the most recent search executed on September 12, 2018. Search strategies were limited to 
English language articles published between January 2013 and September 2018 (see 
Appendix for search strategy details) in order to capture articles more likely to reflect the 
current U.S. opioid epidemic.
Inclusion/Exclusion Criteria.
To identify articles pertaining to A/EAs’ POM, our review inclusion criteria were: 1) 
described human consumption of POs; 2) addressed POM initiation, risk/protective factors, 
access, outcomes, or intervention approaches; 3) reported results for participants ages 10-25; 
4) data collected in the U.S.; 5) included data collected in 2010 or later; 6) written in English 
language; 7) full-length paper (i.e., not a published abstract); and 8) published in a peer-
reviewed journal. Figure 1 details exclusion reasons.
Data Abstraction.
We exported citations from initial database searches into Mendeley Desktop (Elsevier Inc.) 
software, removed duplicates, and then exported unique citations into the systematic review 
software, Rayyan version 1.19.1, for title and abstract review [16]. Two reviewers assessed 
each abstract; a third reviewer resolved disagreements. Two reviewers conducted full-text 
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reviews, further assessing inclusion/exclusion criteria, to identify included articles. We 
reviewed reference lists in five review articles identified in the search [9–12, 17] for 
additional articles to include. We developed an electronic codebook for extracting and 
organizing data items from each article into initial tables with fields to capture study 
purpose, design, data collection methods, intervention description, setting and sample 
characteristics, results, limitations, and conclusions.
Synthesis of Results.
We refined extracted data (Tables 1–4). To inform prevention efforts, we organized articles 
by sample age group (adolescents only [ages 10-17]. EAs only [ages 18-25], or both A/
EAs), data source, including annual nationally representative surveys (e.g., Monitoring the 
Future [MTF]. National Survey on Drug Use and Health [NSDUH]) or other sources, and 
methodology (i.e., cross-sectional, longitudinal cohort, intervention, non-self-reported 
objective data such as medical chart review or insurance claims data), summarizing key 
findings below. Many articles addressed multiple research questions (e.g., prevalence and 
risk factors) and are discussed throughout the results.
Results
Article Identification and Selection.
The EBSCO search resulted in 5,713 citations and the EMBASE search in 2,599, totaling 
8,312. After removing duplicates, we reviewed titles and abstracts of 6,758 articles resulting 
in 458 remaining articles for full-text review, leading to 71 articles meeting inclusion 
criteria. When reviewing references in the identified review articles, we added five papers 
meeting inclusion criteria, resulting in 76 included articles (Figure 1).
Recent Epidemiology of POM.
Tables 1–3 include studies reporting A/EAs’ POM prevalence and epidemiology.
Adolescents.—Two MTF studies reported adolescent POM prevalence, with pooled data 
(1997-2014) indicating lifetime prevalence at 7.6% [18]. In 2010-2011, past-year prevalence 
was 5.5% for Vicodin/OxyContin misuse [19]. NSDUH studies reported past-year POM 
prevalence at 5-6% (ages 12-17; approximately 2008-2013) [20–25], whereas a Minnesota 
high school survey reported 1.67% past-year prevalence [26]. Notably, prevalence data show 
OxyContin misuse was more common among American Indians than overall narcotic use 
and more common in this group than in the general adolescent population [27]. NSDUH 
data suggest that adolescents’ past-year POM prevalence is decreasing, from 7.51% (2002) 
to 4.82% (2014) [28]. See Table 1.
Both Adolescents and Emerging Adults.—As shown in Table 1, among MTF 12th 
graders (A/EAs, given inclusion of age 18), lifetime and past-year POM prevalence were 
10-12% and 8-9%, respectively [29–40]. MTF data from 2015 found lower annual POM 
rates of 3.8-6.0% [41, 42], with decreasing lifetime POM from 12% to 7-8% over 2013-2015 
[32]. NSDUH data show lifetime and past-year rates at 14% [43] and 9.8% [40], 
respectively. Pooling NSDUH data (2002-2013), approximately 1% of 12-13-year-olds 
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initiated POM, which increased for ages 16-17, remained stable for ages 18-19, and declined 
at ages 20-21 [44]. NSDUH data also suggest reductions in past-year POM (most recent data 
for 2014) for A/EAs, with higher rates among EAs [28, 45]; OUD rates have reduced among 
adolescents, but are stable (and higher) or increasing in EAs [28, 45]. PO injection is more 
common for EAs than adolescents [46]. In terms of sources, NSDUH and MTF data show 
that more than half of A/EAs obtain POs from family/friends [29, 47], the most common 
source. When considering people reporting physicians as their PO source in NSDUH data, 
12-25-year-olds were more likely than adults ages 26-49 to report physicians as a source of 
POs used non-medically [47].
In other cross-sectional data, lifetime prevalence was 5.1% in Michigan middle and high 
school students [48], and 18.8% among high school students from West Virginia, Illinois, 
California, New Jersey, and Florida [49]. Among a general sample of Emergency 
Department (ED) patients, past-year POM prevalence was 8.7-10.9% [50, 51]. Regarding 
past 30-day POM, a national survey found 3.2% prevalence among 10-18-year-olds [52] and 
among homeless youth, about 5% reported POM alone plus approximately 2.5% reporting 
POM with concurrent misuse of sedatives or stimulants [53]. Among youth in substance use 
treatment, 16.4% surveyed had lifetime POM [54]. PO poisoning hospitalizations related to 
suicide or self-injury increased between 1997 and 2012 (ages 15-19), as did hospitalizations 
for PO poisonings [55] and Ohio opioid misuse treatment admissions from 2008-2011 [56]. 
Likewise, data show annual increases in A/EA opioid poisoning calls from 2005-2010 [57], 
and 71.5% of PO exposures involve intentional behaviors, with opioid misuse attributable to 
suspected suicide increasing 52.7% (2000-2015) [58]. See Table 2.
Emerging Adults.
From 2008-2010, past-year POM prevalence was 11.3-13.2%, depending on educational 
status [59], although using pooled data (2002-14) another study reported 7.6% past-year 
prevalence [23], consistent with the 2014 rate [28]. EAs comprised 30-35% of all individuals 
reporting past-year POM [60–62]. Among EAs with lifetime POM, PO injection increased 
140% from 2003-2014 [46]. Among college students, past-year POM was 4.9% [63]; 
lifetime prevalence was 3.4-12.1%, depending on PO type [64]. The rate of women’s ED 
visits for opioid misuse/abuse was highest among EAs [65]. EAs with recent POM were 
more likely to report a dealer, friend, or relative (and not physicians) as their source for POs 
[66, 67]. See Table 1.
Demographic, Individual, and Social Risk and Protective Factors.
Adolescents.—In Table 1, Female sex was consistently a demographic risk factor for 
POM [20, 21, 24, 68], as was older age and/or higher grade level [19, 20, 27, 68, 69]. Four 
studies identified White race [19, 20, 54, 68] and one identified Black race [24] as associated 
with higher POM risk while another study found no race differences in POM [22]. 
Adolescents comprised the majority of pediatric ED visits for intentional PO overdoses 
(ages 15-17) [70] and opioid-related adverse events (including self-harm) [71]. Three studies 
reported lower SES [20, 21, 68], whereas, one study found higher SES [72] was a POM risk 
factor. Rural residence and residential instability (1-2 moves in the past 5 years) increased 
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POM risk [24, 73]. Religiosity (e.g., importance, attendance at services) was protective 
against POM [68].
Individual Factors.—Other substance use, including binge drinking [22, 68], was a 
consistent POM risk factor [20, 22, 24, 54, 68, 72], as was perceived ease of obtaining illicit 
drugs [24]. Mental health problems [48], depression [20, 22, 24] or related hospitalization 
[24, 72] were risk factors, as was ED utilization [40]. Adverse childhood events [26] and 
behavioral problems (e.g., suspension, fighting, and delinquency) were also POM risk 
factors [7, 19, 20, 22, 68].
Social Factors.—Negative personal, peer, and parental attitudes toward use were 
protective against POM [22]; positive personal and peer substance use attitudes increased 
risk [69], as did peer substance use [22, 24, 25]. Parenting factors (e.g., high bond, 
involvement, monitoring/warmth) were protective [22, 68, 69]. Youth with lower grades had 
greater POM risk [19, 68]. In MTF data, the association between sports involvement and 
POM was mixed (either no association or protective); however, youth playing football or 
wrestling were at higher risk [18, 19, 39].
Both Adolescents and Emerging Adults.—Different studies identified female [74–
76] and male sex as risk factors [37, 52]. Two MTF reports found minority identities [77], 
and Hispanic/Black identities [37], were protective against POM (vs. White). Among high 
intensity alcohol drinkers, Hispanic, Black, and Other races were associated with increased 
risk of past-month POM (vs. White) [31]. In contrast, American Indians living on/near 
reservations had higher rates of OxyContin use than national samples [27]. Two studies 
found EAs had higher risk than those ages 35+ [45] and 12-17 [46] for POM and PO 
injection. Similarly, two studies found that past-year frequency of narcotic use other than 
heroin [78] and aberrant behaviors (i.e., POM, [79]) were heightened among older A/EAs 
versus younger adolescents. Pregnant A/EAs were more likely to report POM than older 
pregnant women [80]. Religiosity was protective for POM [37]. Socioeconomic risk factors 
included higher weekly student income [37] and having a parent with a college degree [77]. 
Living in a higher density location was protective [37]; residence in the Midwest and West 
increased POM risk [31].
Individual Factors.—Other substance use was a common POM risk factor, including: 
cigarette smoking [35, 77], alcohol/high intensity drinking [31], use of marijuana [31, 35, 
52, 77, 81, 82]. LSD, sedative, barbiturates, and/or stimulants [77, 81], energy drinks [41], 
more frequent heroin use [34], and initiating alcohol or marijuana use before 9th grade [31]. 
Perceived ease of obtaining opioids [38], having an opioid prescription [77] and medical 
opioid use [32], including intravenous opioids received during ED care [51], were also POM 
risk factors. One study found a combined indicator of drinking and driving or riding with a 
drunk driver [51] was a POM risk factor.
Mental health POM risk factors included suicide risk behaviors [49]. Sexual risk behaviors 
were associated with increased POM risk [50]. Although one study found weight lifting and 
wrestling were POM risk factors, and playing soccer was protective [39], another found a 
general increased risk for POM in sports-involved females, but not males [38]. Skipping 
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class [31], lower self-control [38], not using adaptive coping strategies [83] and reporting 
medical misuse motives to reduce pain and to get high [74] were also risk factors.
Social Factors.—One study found a higher frequency of attending raves was a POM risk 
factor [33]. Living with two parents was protective [37].
Emerging Adults.—Demographic POM risk factors included male sex [59], non-Hispanic 
White identity [59], older age (24-26 vs. 18-20, [84]), and lower education/non-college 
involvement [59, 85]. Lower education [59, 86] was a risk factor for OUD; protective factors 
for OUD included Non-Hispanic Black race/ethnicity [59] and college involvement [85]. In 
Medicaid claims (Table 2), EAs were less likely to die of an opioid-related death than older 
ages [87].
Individual Factors.—POM risk factors included psychiatric distress and depression [59, 
64]. Feminine gender orientation (measured distinctly from biological sex) was protective in 
one study [64]. Past-year psychiatric distress was an OUD risk factor [59], whereas using 
POs only to self-medicate was protective [88].
Longitudinal Trajectories of Prescription Opioid Misuse.
Both Adolescents and Emerging Adults.—In Table 3, A/EAs who received a medical 
prescription before age 12 initiated POM earlier than those who did not [89], and 25% of 
students with POM persisted a year later [75]. Continuous sports involvement was a risk 
factor for POM over time for men, but not women [76]. Using surgical claims data (Table 2), 
opioid naive A/EAs had a rate of misuse at 420.6 per 100,000 person years, with time to 
misuse occurring a median of 1.5 years after surgery [90].
Emerging Adults.—One 3-year study followed EAs with POM in Ohio to examine the 
course of POM, finding that 2.8% transitioned to heroin per year ([91], Table 3). Risk factors 
for transition included: White race, PO dependence symptoms, PO initiation at young ages, 
absence of health-related self-medication motives, sniffing/snorting, and more frequent 
POM [91].
Interventions.
Adolescents.: Two articles (Table 4) reported secondary effects on POM of evidence-based 
prevention programs for other substance use among 6th and 7th graders in three cluster-
randomized trials: the Strengthening Families Program (SFP) and the Life Skills Training 
Program (LST). SFP involves six 2-hour sessions for youth and parents, plus one family 
session, focused on parenting skills and family relationships, delivered in the school’s 
community. SFP reduces alcohol and other drug use, and other problem behaviors and 
improves school performance [92]. LST consists of 15 teacher-delivered classes in one year, 
with additional booster lessons in years 2 and 3, focused on personal management, social 
skills, and substance use resistance skills [93]. Although not designed specifically for POM, 
secondary analyses show that SFP and LST resulted in POM reductions at ages 21-25 [94]. 
LST, combined with SFP, was the most effective for POM; however, LST alone had the 
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lowest cost [95]. The combination of SFP and LST was most effective in high-risk youth 
(e.g., 2+ substances) [94].
Discussion
This scoping review discovered that most recent studies of A/EAs’ POM focus on 
epidemiology using annual national surveys (e.g., 42 using NSDUH or MTF, 22 with study-
specific methods, 9 with objective sources). Annual national prevalence estimates range 
from 4.8-7.5% among adolescents [28] and 7.6-13.2% among EAs [23, 59]. Variations likely 
reflect data collection year and differing types and definitions of POM. For example, past-
year prevalence estimates of 12th graders’ nonmedical OxyContin use were about 2.5 times 
higher in MTF than NSDUH; NSDUH’s inclusion of a pictorial pill card could yield more 
precise estimates [40]. Prevalence appears higher in sub-samples (e.g., American Indians, 
pregnant women) and older versus younger A/EAs, supporting the need for increased 
primary prevention programming (for all youth in a setting regardless of risk) earlier in 
adolescence, with more intensive, selective or secondary prevention interventions (given to 
those at-risk) among older adolescents and emerging adults.
Recent data on risk and protective factors could inform personalized interventions and 
determination of sub-groups requiring more intensive interventions. Demographic risk 
factors include sex, with adolescent females having higher POM rates than males. In A/EAs, 
findings for sex were mixed, potentially reflecting motives, with females more commonly 
reporting medical misuse [32] and pain and relaxation motives [96], whereas males and 
females show similar rates of non-medical misuse [32]. Among A/EAs, White race was 
associated with increased POM risk; however, within subpopulations (e.g., high intensity 
drinkers), other races had higher risk. Findings regarding socioeconomic status and POM 
were mixed for A/EAs [20, 21, 37, 72, 77, 80], but lower educational attainment suggests 
increased POM and OUD risk among EAs [59, 85].
Most studies examined individual, and to a lesser extent social, POM risk factors; protective 
factors were under-studied. Among A/EAs, other substance use was a consistent risk factor 
[20, 22, 31, 35, 41, 42, 52, 54, 68, 72, 77, 81, 82]. Upstream approaches to prevent substance 
use initiation among universal samples could prevent POM. Consistent with research 
showing A/EAs often acquire POs from peers [22, 24, 25, 66, 67], peer substance use was a 
social risk factor. As some youth obtained POs from physicians, prescribers are also 
essential in limiting opportunities for use and diversion through adopting prescribing 
guidelines to limit the PO supply. Note, however, prescribing guidelines can have 
unintended effects in that reducing the PO supply from healthcare providers can potentially 
influence individuals to seek out street opioids, which may have greater potency and a 
higher risk profile. Next, other individual POM risk factors across A/EAs included: mental 
health (i.e., depression), behavioral problems (e.g., delinquency, lower academic 
performance), and sexual risk behaviors [19, 20, 22, 24, 31, 49, 50, 68]. Key protective 
factors included religiosity [37, 68], negative POM attitudes, perceived attitudes by social 
influences [22], and family factors (i.e., living with two parents, parental bond; [22, 37, 68]). 
Interventions addressing family and peer influences to prevent diversion or PO access, that 
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also promote prosocial activities (e.g., religious service attendance or analogous secular 
activities) may bolster protective influences for at-risk A/EAs.
Current data pertaining to A/EAs’ longitudinal trajectories of PO use, including risk and 
protective factors for initiation, and escalation from use to misuse and OUD development are 
lacking. The field’s reliance on annual surveys of new cohorts precludes identifying which 
youth need selective prevention efforts to alter risk trajectories in the current opioid 
epidemic. Regarding the trajectory of PO use to misuse, longitudinal data indicate that 
receiving a prescription before age 12 increases risk for initiating misuse [89]. One-third of 
PO users later misuse [77], yet one study found that only 25% of adolescents continued 
POM one year later [75]. Such discrepancies highlight the need for research to identify 
markers of risk for future continued or escalated use. For example, risk factors for future 
POM included substance use whereas disapproval of regular marijuana use and better grades 
were protective [77]. Continuity of athletic involvement increased males’ POM risk, 
presumably due to exposure via sports injuries and/or peer diversion, although cross-
sectional findings for athletic involvement are mixed. Finally, based on objective claims 
data, time from PO pharmacy fill to POM was about 18 months [90], whereas transition 
from POM to heroin misuse varied, occurring for some within a year, but most occurring 
over several years, with younger age of initiation and more frequent POM predicting 
transition [91]. These data, along with those showing PO fills after wisdom teeth extraction 
was more likely among older youth (vs. ages 13-15), and those with known risk factors for 
misuse (i.e., chronic pain, mental health issues, and/or prior prescription drug misuse [e.g., 
sedatives]), underscore the need for careful consideration of prescribing to youth and 
limiting doses [97]. Further, youth with known risk factors may benefit from monitoring and 
selective prevention programs to prevent escalation.
Recommendations for prevention
Implementation of evidence-based prevention interventions across settings for A/EAs at-risk 
for or with POM is urgently needed [98]. The Strengthening Families Program (SFP, [92]) 
and the Life Skills Training Program (LST, [93]; both described at blueprintsprograms.org), 
are promising, multi-session, universal prevention programs for adolescents, with effects 
lasting into emerging adulthood. Notably, selective prevention for at-risk or currently 
misusing A/EAs were lacking. In health care settings, screening to identify substance users, 
followed by brief interventions (Bis) for alcohol (UConnect, [99]) or marijuana (Chill, 
[100]) reduced prescription drug misuse (primarily opioids) among A/EAs. Similarly, Bis 
reduced POM in adults [101, 102]; however, modest BI effect sizes require enhancing. 
Because POM is multi-faceted, prevention interventions for A/EAs must be tailorable to 
individual use patterns, contexts, and severity, addressing motives for medical and non-
medical use [29], other substance use to prevent overdose, and mental health given the role 
of opioids in suicide [103]. Consistent with the promising Bis above, interventions should be 
informed by behavior change theories (i.e., motivational interviewing [104], cognitive 
behavioral therapy [105]).
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Limitations include that studies published outside of January 2013-September 2018 were 
excluded; however, examining recent trends is justified given the recency of the current 
opioid crisis and publication lag meaning that articles published previously are less likely to 
contain data reflecting the current crisis. We did not include non-English and non-U.S. 
articles as our purpose was to inform U.S. prevention approaches; although work from other 
countries could be informative, prevention efforts should be culturally-tailored, therefore, 
U.S. data was most relevant for our purposes. Consistent with about half of published 
scoping reviews [106], we did not include grey literature. We focused on peer-reviewed 
research publications to identify evidence-based interventions and to provide an overview of 
current research. Excluding grey literature means that we may have missed some promising 
programs or unique information not represented in the peer-reviewed literature. Although it 
was beyond the scope of this prevention-focused review to examine legislation or public 
policy efforts, future reviews are warranted as such approaches can have intended and 
unintended consequences. For example, a recent study demonstrated that implementing 
comprehensive legislation mandates (i.e., Kentucky prescriber education, PDMP registration 
and usage) had the greatest impact on POM and heroin use among ED patients ages 18-24. 
While POM reduced by 73%, heroin use increased by 362% [107]. Finally, we did not 
examine substance use treatment interventions and youth with OUDs receiving treatment 
services (e.g., medication assisted treatment), given our prevention focus, which is a separate 
literature requiring future examination.
Directions for future research
Prevention research for A/EAs is needed in several key areas. First, although cross-sectional 
studies suggest many risk and protective factors, longitudinal examination of initiation and 
escalation of POM to identify how these factors influence trajectories of PO use to POM and 
related outcomes is needed. Research on risk and protective factors also lacks a unifying 
theoretical framework to guide construct inclusion. Second, research is needed to develop, 
test, and implement evidence-based, universal and selective interventions for the current, 
heterogeneous context of POM, which to date consist of secondary data analyses of opioid-
related outcomes from programs targeting other substance use. The most efficient route to 
creating efficacious, scalable interventions could include adapting promising programs, such 
as community- and school-based universal prevention programs (e.g., Strengthening 
Families Program [92]. Life Skills Training Program [93]) and health care-based universal 
and selective prevention programs (UConnect [99]. Chill [100]) for the current POM context 
and generation of A/EAs. Similarly, recent evidence-based selective interventions for at-risk 
adults [101, 102]) could be revised for developmental relevance to A/EAs. Use of 
optimization frameworks (e.g., Multiphase Optimization Strategy [108]) and hybrid 
effectiveness-implementation designs [109], paired with cost-effectiveness measures to 
inform sustainability [95], could facilitate rapid impact of such interventions on preventing 
POM among A/EAs. Third, we again recognize the need for research on the impact of 
policies/legislation to reduce supply and diversion, given the vast majority of A/EAs obtain 
POs from family or friends [28, 45, 64, 65], which is particularly urgent given demonstrated 
unintended consequences of reducing the PO supply on heroin use [107]. Note that until 
efficacious prevention programs are in place, POM will continue, with some A/EAs 
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escalating to OUD, thus the efficacy of addiction treatments for A/EA OUD should be 
examined.
Conclusion
Although prevalence varies, about one in twenty adolescents and one in ten EAs currently 
report POM, heightening risk for morbidity and mortality, as reflected in recent alarming 
rises in opioid poisoning deaths among A/EAs [1, 110]. Given this developmental peak in 
POM, early prevention is urgently needed to deter serious consequences (e.g., intentional 
and unintentional opioid overdose, other injury), especially for those with additional risks 
for adverse outcomes (e.g., substance use, mental health), and to prevent OUD. Partnering 
with community stakeholders (e.g., Families Against Narcotics) and using a participatory 
action approach [111] could help adapt promising programs [100–102, 112], to facilitate 
sustainable prevention approaches in communities. Specifically, engaging community 
stakeholders, and youth in particular, via participatory action-based partnerships (e.g., focus 
groups, co-design, planned implementation) can have the advantages of improving cultural 
relevance, promoting uptake of interventions and sustainability, and ensuring that 
interventions reflect current trends and terminology. Although longitudinal data is clearly 
needed to understand transitions from PO initiation, escalation to POM, and development of 
OUDs, in the meantime, hybrid effective implementation designs [109] could be used to 
accelerate translation of evidenced-based programs, including universal prevention programs 
(e.g., Strengthening Families Program) in schools and communities, and screening for POM 
and related risk factors in health care settings, followed by delivery of selective prevention 
interventions [99–102].
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• Most identified studies examined epidemiology of youth prescription opioid 
misuse.
• Few studies explore opioid misuse trajectories or prevention program efficacy.
• Future youth prevention research in these two areas is urgently needed.
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